Fatigue News and Research RSS Feed - Fatigue News and Research

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]
Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014. [More]
MS study uses fNIRS to examine brain activation during working memory task

MS study uses fNIRS to examine brain activation during working memory task

Using functional near infrared spectroscopy (fNIRS), Kessler Foundation researchers have shown differential brain activation patterns between people with multiple sclerosis (MS) and healthy controls. [More]
Initiatives to reduce deaths from heart failure for patients worldwide

Initiatives to reduce deaths from heart failure for patients worldwide

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) is calling for global policy change relating to heart failure. An international white paper, Heart failure: preventing disease and death worldwide, was published in May 2014. [More]
New technology holds potential to identify cardiac disease using video monitoring

New technology holds potential to identify cardiac disease using video monitoring

To the careful observer, a person's face has long provided insight into what is going on beneath the surface. Now, with the assistance of a web camera and software algorithms, the face can also reveal whether or not an individual is experiencing atrial fibrillation, a treatable but potentially dangerous heart condition. [More]
Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. [More]
Millions of women suffering in silence with hot flashes

Millions of women suffering in silence with hot flashes

The steep decline in the use of hormone therapy has spawned a prevalent but preventable side effect: millions of women suffering in silence with hot flashes, according to a study by a Yale School of Medicine researcher and colleagues. [More]
Experimental drug shows promise as viable treatment for anemia of inflammation

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology. [More]
Low dose of opioids including methadone effective for treatment of testosterone suppression

Low dose of opioids including methadone effective for treatment of testosterone suppression

Treatment for opioid addiction tampers with the testosterone levels of male but not female opioid users, McMaster University research has shown. [More]
Persons with MS may be able to improve self-awareness via task-oriented cognitive rehabilitation

Persons with MS may be able to improve self-awareness via task-oriented cognitive rehabilitation

A new study of self-awareness by Kessler Foundation researchers shows that persons with multiple sclerosis (MS) may be able to improve their self-awareness through task-oriented cognitive rehabilitation. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Researchers examine effect of sleeplessness on obesity in teenagers over time

Researchers examine effect of sleeplessness on obesity in teenagers over time

Teenagers who don't get enough sleep may wake up to worse consequences than nodding off during chemistry class. According to new research, risk of being obese by age 21 was 20 percent higher among 16-year-olds who got less than six hours of sleep a night, compared with their peers who slumbered more than eight hours. [More]
Dopamine therapy linked to increased impulse control disorders, daytime sleepiness in early PD patients

Dopamine therapy linked to increased impulse control disorders, daytime sleepiness in early PD patients

New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general population. [More]
Dopamine replacement therapy increases impulse control disorders in newly diagnosed PD patients

Dopamine replacement therapy increases impulse control disorders in newly diagnosed PD patients

New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general population. [More]
Researchers examine skin creams that contains toxic mercury much faster than before

Researchers examine skin creams that contains toxic mercury much faster than before

As countries try to rid themselves of toxic mercury pollution, some people are slathering and even injecting creams containing the metal onto or under their skin to lighten it, putting themselves and others at risk for serious health problems. [More]
First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma. [More]
People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from a rare illness, the Mal de Debarquement Syndrome (MdDS), now have a chance for full recovery thanks to treatment developed by researchers at the Icahn School of Medicine at Mount Sinai. [More]
CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. [More]
UMass Amherst researcher receives grant to uncover molecular mechanisms of skeletal muscle fatigue

UMass Amherst researcher receives grant to uncover molecular mechanisms of skeletal muscle fatigue

Muscle physiologist Edward Debold at the University of Massachusetts Amherst's School of Public Health and Health Sciences recently received a three-year, $198,000 grant from the American Heart Association to support studies to uncover the molecular mechanisms of skeletal muscle fatigue. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]